2 completed, 1 recruiting, 1 unknown. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Optic Nerve Injuries: new trials by email Literature Review of Optic Nerve Injuries trials Research Report on Optic Nerve Injuries
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml, Placebo of G01 Eye Drops - Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 90 | 2026-03-18 | 2026-08-24 |
| Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. Recombinant human erythropoietin 4,000 UI and 2,000 UI, Methylprednisolone succinate 500 mg - Toxic Optic Neuropathy, Treatment | Phase 2 / Phase 3 | Unknown | Asociación para Evitar la Ceguera en México | 18 | 2022-04-05 | 2023-02-28 |
| Traumatic Optic Neuropathy Treatment Trial (TONTT) Recombinant human erythropoietin (EPO), Observation, Methyl prednisolone - Traumatic Optic Neuropathy | Phase 1 / Phase 2 | Completed | Tehran University of Medical Sciences | 117 | 2015-02-01 | 2019-05-07 |
| Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). RPh201, Placebo - Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries | Phase 2 | Completed | Regenera Pharma Ltd | 22 | 2014-02-01 | 2020-03-19 |
Glaucoma, Open-Angle (1) · Optic Neuropathy, Ischemic (1) · Toxic Optic Neuropathy (1)
Cranial Nerve Diseases (4) · Cranial Nerve Injuries (4) · Craniocerebral Trauma (4) · Eye Diseases (4) · Nervous System Diseases (4) · Optic Nerve Diseases (4) · Trauma, Nervous System (4) · Wounds and Injuries (4) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Glaucoma (1) · Ocular Hypertension (1) · Pathologic Processes (1)
Control Groups (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1) · Observation (1)
Asociación para Evitar la Ceguera en México (1) · Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. (1) · Regenera Pharma Ltd (1) · Tehran University of Medical Sciences (1)
China (1) · Iran (1) · Israel (1) · Mexico (1)
Mohsen B Kashkouli, MD (1) · Octavio Turcio-Aceves, MD (1) · Yuanbo Liang (1) · Zvi Segal,, MD (1)